Secondary hyperthyroidism Cinacalcet,
Conditions
Interventions
CKD stage 4-
5 with secondary hyperparathyroidism
Treatment
Sponsors
Chulalongkorn University
Chulalongkorn University
Eligibility
Sex/Gender
All
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 1. chronic kidney disease patietns with GFR ≤ 3o ml / min 2. secondary hyperparathyroidism 3. age > 18 years 4. received cinacalcet treatment for at least 12 weeks
Exclusion criteria
Exclusion criteria: 1. liver function tests > 2 × the upper limit of normal 2. received drugs which may significantly influent exposure to cincacalcet including: ketoconazole, erythromycin, itraconazole, clarithromycin, voriconazole, atazanavir, indinavir, or ritonavir) 3. patients who had incomplete medical records
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| parathyroid hormone level 12 weeks chemiluminescence immunoassay | — |
Secondary
| Measure | Time frame |
|---|---|
| serum calcium 4 weeks Modification of the calcium o – cresolphthalein complexone | — |
Contacts
Public ContactSomratai Vadcharavivad
Faculty of Pharmaceutical Sciences, Chulalongkorn University
Outcome results
None listed